Q32 Bio: Positive Phase-2 Data on Bempikibart - H.C. Wainwright Sees 134% Price Potential!
Reading Time: 4 minutes
The biotech company Q32 Bio (QTTB) released encouraging 36-week results from the Phase 2a study of Bempikibart for alopecia areata on July 13. Immediately following the positive market reaction to the data, management took advantage of the favorable market environment to raise capital amounting to USD 200 million. Today, on July 28, the research firm H.C. Wainwright reacted to the developments, significantly raised the price target from USD 13 to USD 36, and reaffirmed its buy recommendation for the stock. Tipping Point After Earlier Setbacks...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
